HPV Vaccine

About HPV

  • Human papillomavirus (HPV) is the most common sexually transmitted infection in the United States. There are more than 200 strains (and counting). In the vast majority of cases it causes no health problems and completely clears on its own.

Why HPV vaccines are unnecessary

  • More than 90% of HPV infections clear on their own
  • Regular pap smears are still needed and are very effective at preventing cervical cancer by early intervention
  • Precancerous lesions are curable
  • Maintaining a healthy diet and lifestyle further reduces risk of HPV complications
  • https://report.nih.gov/nihfactsheets/viewfactsheet.aspx?csid=76

Why HPV vaccine impact on cancer unknown

  • It takes on average 30 years for cancer to develop in the rare cases when HPV infection does lead to cancer. The impact of vaccination programs is not yet known.
  • Strain replacement  has been found to occur. There are more than 200 strains of HPV. While the current Gardasil9 vaccine protects against what are thought to be the strains leading to the most cancer, It is not known what impact other strains may have on cancer rates or on other health conditions. “The number of studies that show that partial immunization via available HPV (human papillomavirus) vaccines is not only insufficient at reducing overall HPV infection rates; the vaccines actually cause rarer, more lethal types of HPV to sweep in and the net effect could be devastating increases in HPV-related cancers.” Dr. James Lyons-Weiler.
  • Cervical cancers after human papillomavirus vaccination.CONCLUSION: Long-term follow-up data are needed to evaluate the prophylactic effectiveness of the current HPV vaccine. These cases could represent non-vaccine-related HPV infections. Young women must be thoroughly counseled about the efficacy and limitations of the vaccine and about continuing lifelong.” PMID 19155953

  • Endocervical Carcinogenesis and HPV Vaccination: An Occasional Circumstance or a Gap in the Chain? “In conclusion, this case report highlights the need for diagnostic surveillance regarding HPV-related cervical cancer even after vaccination.” PMID 28116194

Why the science on HPV vaccination is not settled

New July 2017: Human papilloma virus and lupus: the virus, the vaccine and the disease.

“We review clinical, epidemiological and molecular data suggesting involvement of HPV infection in the pathogenesis of SLE. We suggest that these findings may justify the development of new HPV vaccines containing viral peptides that bear no homology to the human proteome, in order to avoid possible adverse immune cross-reactivity.”

Excerpt from: NVIC

“As of September 1, 2015, there had been 295 claims filed in the federal Vaccine Injury Compensation Program (VICP) for injuries and deaths following HPV vaccination, including 13 deaths and 282 serious injuries.

Using the MedAlerts search engine, as of Sept. 30, 2015, there were a total of 37,474 vaccine reaction reports made to the federal Vaccine Adverse Events Reporting System (VAERS) associated with Gardasil vaccinations, including 209 deaths. There were a total of 3,119 vaccine adverse reaction reports made to VAERS associated with Cervarix vaccinations, including 16 deaths. (Merck’s Gardasil vaccine, which was the first HPV vaccine licensed in the U.S., has the majority of the HPV vaccine market in the U.S.).”

Excerpt from FDA on HPV Clinical Trials:

2.4.1 Clinical Trials with GARDASIL 9

GARDASIL 9  was studied in 6 clinical trials:

Study V503-001was a Phase 2b/3 efficacy study that enrolled 15,457 women 16through 26 years of age and randomized to receive GARDASIL 9 (low-dose, mid-dose, high-dose) or GARDASIL (comparator). The optimal dose for further investigation was defined as the “mid-dose.” This study demonstrated efficacy of 96.7% in terms of prevention of combined genital lesions (CIN2+, VIN2+, orVaIN2+) attributed to the 5 additional HPV types not present in GARDASIL.

Study V503-002was an– immunobridging study linking clinical efficacy obtained from Study V503-001 to 955 children 9 through 15 years of age. Evaluation of clinical efficacy was not feasible because performing genital examination in this population in the absence of the primary endpoint was not justifiable. Non-inferiority was demonstrated for all 9 vaccine HPV types, and lot consistency criteria were also met for the 9 vaccine HPV types.

Study V503-009 was an additional immunological bridging study (not conducted under IND) in 600 females 9 through 15 years of age which demonstrated non-inferior GMT ratios for HPV types 6, 11, 16, and 18 between GARDASIL 9 and GARDASIL

There were 3 studies evaluating vaccine coadministration: V503-005– assessment of potential interference of Gardasil 9 with concomitant Menactra and Adacel inc hildren 11 through 15 years of age V503-006-safety and immunogenicity study of Gardasil 9 in subjects  previously vaccinated with the HPV vaccine V503-007-concomitant administration study with a non-U.S.-licensed vaccine (Repevax); provided safety data for GARDASIL 9i n adolescents11 through 15 years of age

Pharmaceutical Companies’ Role in State Vaccination Policymaking: The Case of HPV

 

Save

Save

Save

Save

Save

Save

Save

Save

Save

Save

Save